Genmab signs asset exchange deal with Medarex
Denmark's Genmab A/S says it has executed an asset exchange agreement with Medarex of the USA. Under the terms of the deal, Genmab will receive full rights to HuMax-Inflam/MDX-018, which targets interleukin-8, and the US firm will gain full rights to multiple disease programs in oncology. The companies will release to each other all previously-held economic interests in the assets exchanged.
"Genmab will now hold all the rights to the HuMax-Inflam antibody which we have developed in cooperation with Medarex and hope to move the product into further clinical studies soon," said Lisa Drakeman, chief executive of the Danish group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze